A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

por Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Imamura, Takumi, Sonoyama, Takuhiro, Ichihashi, Genki, Sanaki, Takao, Tsuge, Yuko, Uehara, Takeki, Mukae, Hiroshi
Publicado 2023

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

por Mukae, Hiroshi, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Sakaguchi, Hiroki, Sonoyama, Takuhiro, Ichihashi, Genki, Sanaki, Takao, Baba, Keiko, Tsuge, Yuko, Uehara, Takeki
Publicado 2022

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infe...

por Mukae, Hiroshi, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Imamura, Takumi, Sonoyama, Takuhiro, Fukuhara, Takahiro, Ichihashi, Genki, Sanaki, Takao, Baba, Keiko, Takeda, Yosuke, Tsuge, Yuko, Uehara, Takeki
Publicado 2022